leisure time -WSS

leisure time

author：fashion 2025-08-12 09:13:04 - browse：6

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

In an abrupt change of course from plans earlier in the month, at-home test maker Cue Health is laying off all of its employees and shutting down as of Friday, May 24.

The company, which grew to prominence during the Covid-19 pandemic as the maker of one of the only molecular at-home tests for the virus, has been teetering on the edge of insolvency for months. The shutdown, first reported by the San Diego Union-Tribune, comes just over a week after the FDA warned consumers not to use Cue’s only FDA-authorized product, a Covid-19 test kit.

Cue had previously notified 49% of its workers on May 1 that they would be laid off from the company, effective July 1. But in a WARN notice filed with California state regulators on May 20, chief human resources officer Allison Blackwell said that due to the “fluid nature of this situation,” all U.S. employees who had not already received notice of termination would be receiving one. All employees will receive their last paychecks on May 24, the notice said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： The surgeon had a dilemma only a Nazi medical text could resolve

WSS

Independent physicians launch a new lobbying group

Dewpoint Therapeutics lays off staff after losing partnerships

World's first CRISPR

Test for long Covid? Researchers find new clue in blood samples

Why doctors need education on FDA device approval process

FDA's Woodcock to retire early next year

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Drug repurposing or repositioning? The language matters

Why doctors need education on FDA device approval process

How one medical school became remarkably diverse

Anthos stroke drug appears safer than common blood thinner

State Dept. review finds Biden bears some blame for Afghanistan failures

World's first CRISPR

23andMe had bad news about my health. I wish a person had delivered it

Biotech venture capitalists face new demands from investors

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

hotspot

Readout Newsletter: Merck, J&J, and long Covid

Independent physicians launch a new lobbying group

FDA's Woodcock to retire early next year

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Wegovy, Zepbound and weight loss drugs that preserve muscle

focus

Wikipedia

hotspot

focus